|
|
|
|
LEADER |
02268nam a2200289 u 4500 |
001 |
EB001897046 |
003 |
EBX01000000000000001060051 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
200523 r ||| eng |
245 |
0 |
0 |
|a Addendum to clinical guideline 30
|h Elektronische Ressource
|b long-acting reversible contraception
|c commissioned by the National Institute for Health and Care Excellence
|
246 |
3 |
1 |
|a Long-acting reversible contraception
|
246 |
3 |
1 |
|a Clinical Guideline 30.1, Long-acting reversible contraception
|
260 |
|
|
|a London
|b National Institute for Health and Care Excellence (UK)
|c September 2014, 2014
|
300 |
|
|
|a 1 PDF file (107 pages)
|b illustrations
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Drug Implants
|
653 |
|
|
|a Contraceptive Agents, Female
|
653 |
|
|
|a Long-Acting Reversible Contraception
|
710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
490 |
0 |
|
|a Clinical guideline addendum
|
500 |
|
|
|a "This replaces chapter 7: Progestogen-only subdermal implants (POSDIs) in clinical guideline 30."
|
856 |
4 |
0 |
|u http://www.ncbi.nlm.nih.gov/books/NBK550932
|3 Volltext
|
082 |
0 |
|
|a 580
|
520 |
|
|
|a The NICE surveillance programme reviewed the guideline on Long-acting reversible contraception (NICE clinical guideline 30) in 2011, and found changes to product licensing that affected the section of the guideline on progestogen-only subdermal implants. The full report can be found here: http://www.nice.org.uk/CG30/ New recommendations relating to progestogen-only subdermal implants have been made in this addendum. You are invited to comment on these new recommendations. Some recommendations can be made with more certainty than others. The wording used in the recommendations in this addendum denotes the certainty with which the recommendation is made (the strength of the recommendation). For all recommendations, NICE expects that there is discussion with the patient about the risks and benefits of the interventions, and their values and preferences. This discussion aims to help them to reach a fully informed decision (see also 'Patient-centred care')
|